Genetic Technologies Ltd

GENE20 Nov 2024
Healthcare
$0.79
-0.02 (-1.96%)
Lowest Today
$0.77
Highest Today
$0.79
Today’s Open
$0.79
Prev. Close
$0.77
52 Week High
$3.59
52 Week Low
$0.67
To Invest in Genetic Technologies Ltd

Genetic Technologies Ltd

Healthcare
GENE20 Nov 2024
-0.02 (-1.96%)
1M
3M
6M
1Y
5Y
No Data Available
Low
$0.76
Day’s Range
High
$0.79
0.76
52 Week Low
$0.67
52-Week Range
52 Week High
$3.59
0.67
1 Day
-
1 Week
-
1 month return
-
3 month return
-6.34%
6 month return
-55.75%
1 Year return
-70.83%
3 Years return
-92.62%
5 Years return
-92.01%
10 Years return
-
Institutional Holdings
Susquehanna International Group, LLP
0.57
Morgan Stanley - Brokerage Accounts
0.4
BNP Paribas Arbitrage, SA
0.31
TWO SIGMA SECURITIES, LLC
0.3
UBS Group AG
0.18
Rhumbline Advisers
0.08
Citadel Advisors Llc
0.01
Fundamentals
Market Cap
3.71 mln
PB Ratio
3.14
PE Ratio
0
Enterprise Value
3.56 mln
Total Assets
6.19 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. The company also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, it offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. It has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery; and research collaboration with Harvard University, Ohio State University, and Washington University. The company was incorporated in 1987 and is headquartered in Prahran, Australia.
Organisation
Genetic Technologies Ltd
Employees
55
Industry
Diagnostics & Research
CEO
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step